2011•白血病·淋巴瘤Requires access

Research progress of bortezomib therapy in patients with relapsed or refractory mantle cell lymphoma

Yang Ding, Xiaomeng Wang

Abstract

Currently refractory and relapsed mantle cell lymphoma (MCL) continues to develope a poor prognosis, and the treatment remains a significant clinical challenge. The use of bortezomib in clinic provides a novel method for the treatment of refractory and relapsed MCL. This review summarizes the mechanism and efficiency of bortezomib in the treatment of MCL and the strategies for overcome of bortezomib resistance. Key words: Lymphoma, mantle-cell; Bortezomib; Therapy

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Bortezomib, Mantle cell lymphoma, Medicine, Refractory (planetary science), Lymphoma, Oncology, Mantle (geology), Internal medicine